Evidence map›Paper›PMID 38500663›Full record

ArticleFrontiers in oncology2024

Extracellular vesicles as a new frontier of diagnostic biomarkers in osteosarcoma diseases: a bibliometric and visualized study.

Yanhong Pei, Yu Guo, Wei Wang, Boyang Wang, Fanwei Zeng, Qianyu Shi, Jiuhui Xu, Lei Guo, Chaowei Ding, Xiangpang Xie and 2 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Tumor microenvironment: new era in exosomal circRNA research - a bibliometric analysis.Extracellular vesicles and circulating nucleic acids · 2025
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yanhong PeiMusculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China.
Yu GuoMusculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China.
Wei WangMusculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China.
Boyang WangMusculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China.
Fanwei ZengMusculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China.
Qianyu ShiMusculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China.
Jiuhui XuMusculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China.
Lei GuoMusculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China.
Chaowei DingMusculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China.
Xiangpang XieDepartment of Hepatobiliary and Pancreatic Surgery, The Affiliated Cangnan Hospital of Wenzhou Medical University, Cangnan, Zhejiang, China.
Tingting RenMusculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China.
Wei GuoMusculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of liquid biopsy in cancer research has grown exponentially, offering potential for early detection, treatment stratification, and monitoring residual disease and recurrence. Exosomes, released by cancer cells, contain tumor-derived materials and are stable in biofluids, making them valuable biomarkers for clinical evaluation. Bibliometric research on osteosarcoma (OS) and exosome-derived diagnostic biomarkers is scarce. Therefore, we aimed to conduct a bibliometric evaluation of studies on OS and exosome-derived biomarkers. Using the Web of Science Core Collection database, Microsoft Excel, the R "Bibliometrix" package, CiteSpace, and VOSviewer software, quantitative analyses of the country, author, annual publications, journals, institutions, and keywords of studies on exosome-derived biomarkers for OS from 1995 to 2023 were performed. High-quality records (average citation rate ≥ 10/year) were filtered. The corresponding authors were mainly from China, the USA, Australia, and Canada. The University of Kansas Medical Center, National Cancer Center, Japan, and University of Kansas were major institutions, with limited cooperation reported by the University of Kansas Medical Center. Keyword analysis revealed a shift from cancer progression to mesenchymal stem cells, exosome expression, biogenesis, and prognostic biomarkers. Qualitative analysis highlighted exosome cargo, including miRNAs, circRNAs, lncRNAs, and proteins, as potential diagnostic OS biomarkers. This research emphasizes the rapid enhancement of exosomes as a diagnostic frontier, offering guidance for the clinical application of exosome-based liquid biopsy in OS, contributing to the evolving landscape of cancer diagnosis.

Indexed as

bibliometric analysisbiomarkerexosomeliquid biopsyosteosarcoma

Identifiers

PMID38500663
PMCPMC10944918

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.